BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33781907)

  • 21. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive pneumococcal disease in Northern Alberta, not a Red Queen but a dark horse.
    Marrie TJ; Tyrrell GJ; Majumdar SR; Eurich DT
    Vaccine; 2018 May; 36(21):2985-2990. PubMed ID: 29685595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive pneumococcal disease in patients with haematological malignancies before routine use of conjugate vaccines in Finland.
    Lindström V; Aittoniemi J; Lyytikäinen O; Klemets P; Ollgren J; Silvennoinen R; Nuorti JP; Sinisalo M
    Infect Dis (Lond); 2016; 48(5):399-402. PubMed ID: 26635103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.
    Hsu K; Pelton S; Karumuri S; Heisey-Grove D; Klein J;
    Pediatr Infect Dis J; 2005 Jan; 24(1):17-23. PubMed ID: 15665705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes.
    Lehmann D; Willis J; Moore HC; Giele C; Murphy D; Keil AD; Harrison C; Bayley K; Watson M; Richmond P
    Clin Infect Dis; 2010 Jun; 50(11):1477-86. PubMed ID: 20420501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Euro Surveill; 2017 Mar; 22(10):. PubMed ID: 28300529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Pandemic and Nonpandemic Influenza Periods.
    Hernández S; Muñoz-Almagro C; Ciruela P; Soldevila N; Izquierdo C; Codina MG; Díaz A; Moraga-Llop F; García-García JJ; Domínguez Á
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31189583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme.
    Harboe ZB; Valentiner-Branth P; Benfield TL; Christensen JJ; Andersen PH; Howitz M; Krogfelt KA; Lambertsen L; Konradsen HB
    Vaccine; 2010 Mar; 28(14):2642-7. PubMed ID: 20096392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies.
    Wong A; Marrie TJ; Garg S; Kellner JD; Tyrrell GJ;
    Epidemiol Infect; 2010 Dec; 138(12):1804-10. PubMed ID: 20429967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
    Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.
    Andrade AL; Minamisava R; Policena G; Cristo EB; Domingues CM; de Cunto Brandileone MC; Almeida SC; Toscano CM; Bierrenbach AL
    Hum Vaccin Immunother; 2016; 12(2):285-92. PubMed ID: 26905679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.
    Slotved HC; Dalby T; Hoffmann S
    Vaccine; 2016 Feb; 34(6):769-74. PubMed ID: 26772630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.
    Bruce MG; Singleton R; Bulkow L; Rudolph K; Zulz T; Gounder P; Hurlburt D; Bruden D; Hennessy T
    Vaccine; 2015 Sep; 33(38):4813-9. PubMed ID: 26247901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive Pneumococcal Disease in UK Children <1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now?
    Kent A; Makwana A; Sheppard CL; Collins S; Fry NK; Heath PT; Ramsay M; Ladhani SN
    Clin Infect Dis; 2019 Jun; 69(1):84-90. PubMed ID: 30281069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting.
    Johnstone SL; Moore DP; Klugman KP; Madhi SA; Groome MJ
    Paediatr Int Child Health; 2020 Feb; 40(1):50-57. PubMed ID: 31156062
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
    Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive pneumococcal disease among children younger than 5 years of age before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco.
    Diawara I; Zerouali K; Katfy K; Zaki B; Belabbes H; Najib J; Elmdaghri N
    Int J Infect Dis; 2015 Nov; 40():95-101. PubMed ID: 26434380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.